What the business is, and whether it's a good one at a fair price.
Develops and manufactures animal vaccines, with FY26 revenue of Rs. 332.599 crore split between Poultry Healthcare (61.9% of segment revenue) and Animal Healthcare (38.1%). The Poultry Healthcare division sells vaccines for commercial poultry flocks, including an H9N2 Avian Influenza vaccine whose marketing and manufacturing licenses were received in Q4 FY26; it grew 21% for FY26 and 48% YoY in Q1 FY27, driven by deeper market penetration and institutional business. The Animal Healthcare division sells livestock vaccines such as PPR (Peste des Petits Ruminants), Lumpy Skin Disease and Goat Pox, with the bulk of volume going to government immunization tenders — Q4 FY26 saw 6.3 crore PPR doses supplied under the National PPR program. Manufacturing runs across BSL-3 and Fill-Finish facilities capitalized in FY26, with capacity utilization stated at around 60-65%. International operations are anchored by Hester Africa (Nepal and Africa operations), which suffered a weak Q1 FY27 and saw its Gates Foundation soft loan cut from USD 12M to USD 5M interest-free. The largest cost lines are other operating expenses (30.5% of revenue), materials (21.2%) and employees (18.8%), with depreciation at 5.7%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from HESTER BIOSCIENCES LTD's filed financials and exchange disclosures
HESTER BIOSCIENCES LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol HESTERBIO.
Yes. Over the trailing twelve months HESTER BIOSCIENCES LTD reported a net profit of ₹137 Cr on revenue of ₹326 Cr.
Yes. The dividend yield is 0.31% at the current price. It paid out 11% of its profit as dividend in FY26.
No. Debt stands at 0.51× equity, and it carries net debt of ₹185 Cr. That is lower than 17% of its 171 Pharmaceuticals peers.
On trailing P/E, HESTER BIOSCIENCES LTD ranks 39 of 169 in Pharmaceuticals — cheaper than 77% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session HESTER BIOSCIENCES LTD moves 1.07% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by HESTER BIOSCIENCES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
